Proactive Investors
08 Jul 2026, 06:44 UTC · 2h ago
Futura to appeal European patent decision
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
08 Jul 2026, 06:44 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
The European Patent Office decided to revoke Futura Medical's patent for its erectile dysfunction treatment, MED3000 (Eroxon). — Loss of patent protection threatens the long-term exclusivity and pricing power of a core product, creating significant downside risk.
-0.80Futura Medical is pursuing a new US commercial partnership for Eroxon. — Expansion into the US market represents a significant growth catalyst that could offset regional patent risks.
+0.40The patent for MED3000 remains in force while the appeal is pending. — Prevents immediate generic competition, preserving short-term revenue streams and market position.
+0.30Continue reading
6 related stories
Search tags
Futura Medical is appealing the EPO decision, a process expected to take 18 to 24 months. — While an appeal provides a path to recovery, the long timeline creates prolonged uncertainty for investors.
Which stocks this story touches
The company is appealing a European Patent Office decision to revoke a patent for its erectile dysfunction treatment.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Reuters
16h ago
